ArchivesMagazine - 03 Aug 2017Can AstraZeneca recover from failed cancer trial? Mixed views on the drug company’s prospects as dividend fears surface 03 August 2017|Feature|by Lisa-Marie Janes Share on Facebook Share on Bluesky Share on X (Twitter) Share by Email < Surgical Innovations to buy Elemental Healthcare Why payment companies are so attractive > Issue: 03 Aug 2017 - Page 38 | Contents Next: Why payment companies are so attractive Previous: Surgical Innovations to buy Elemental Healthcare Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account. Share on Facebook Share on Bluesky Share on X (Twitter) Share by Email Lisa-Marie Janes Issue Contents Editor's View What dollar dive means for markets Feature Rightmove has solid foundations Fevertree is full of fizz Ceres facing cash bonfire Bank bashing not over yet UK car manufacturing falls on Brexit uncertainty Why payment companies are so attractive Chinese Internet Stars The small caps which could succeed where Astra failed Can AstraZeneca recover from failed cancer trial? Victoria’s a compelling growth yarn Investors panic after Augean issues warning Surgical Innovations to buy Elemental Healthcare Tarsus to take off in second half Monitise cranks up takeover pressure Funds Join the 20% club Great Ideas Alfa by name and performance Bag Mulberry for global growth Switch on to ITV Bank well-earned Sophos profit Time to sell Clipper Logistics? Diageo’s reassuringly expensive Investment Trusts Four ways to use investment trusts News HSBC back to expansion Why tobacco earnings won’t go up in smoke Can BP and Shell deliver on dividends? FDM beats again Personal Finance Weighing up the Vanguard LifeStrategy funds Lessons from the pension freedoms
